CN114787160B - 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物 - Google Patents

作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物 Download PDF

Info

Publication number
CN114787160B
CN114787160B CN201980092367.1A CN201980092367A CN114787160B CN 114787160 B CN114787160 B CN 114787160B CN 201980092367 A CN201980092367 A CN 201980092367A CN 114787160 B CN114787160 B CN 114787160B
Authority
CN
China
Prior art keywords
independently selected
methyl
alkyl
phenyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980092367.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114787160A (zh
Inventor
潘俊
J·罗奇
梅松
何春红
吴亮星
姚文清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to CN202510176623.2A priority Critical patent/CN120208959A/zh
Publication of CN114787160A publication Critical patent/CN114787160A/zh
Application granted granted Critical
Publication of CN114787160B publication Critical patent/CN114787160B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980092367.1A 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物 Active CN114787160B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510176623.2A CN120208959A (zh) 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US62/782,994 2018-12-20
US201962935891P 2019-11-15 2019-11-15
US62/935,891 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510176623.2A Division CN120208959A (zh) 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物

Publications (2)

Publication Number Publication Date
CN114787160A CN114787160A (zh) 2022-07-22
CN114787160B true CN114787160B (zh) 2025-03-25

Family

ID=69467674

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980092367.1A Active CN114787160B (zh) 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物
CN202510176623.2A Pending CN120208959A (zh) 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510176623.2A Pending CN120208959A (zh) 2018-12-20 2019-12-19 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物

Country Status (20)

Country Link
US (3) US11459329B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898627A1 (cg-RX-API-DMAC7.html)
JP (2) JP7414827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210116488A (cg-RX-API-DMAC7.html)
CN (2) CN114787160B (cg-RX-API-DMAC7.html)
AU (1) AU2019401649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011948A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210336A (cg-RX-API-DMAC7.html)
EC (1) ECSP21044843A (cg-RX-API-DMAC7.html)
IL (2) IL318278A (cg-RX-API-DMAC7.html)
MA (1) MA54551A (cg-RX-API-DMAC7.html)
MX (1) MX2021007426A (cg-RX-API-DMAC7.html)
PE (1) PE20220277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106582YA (cg-RX-API-DMAC7.html)
TW (2) TW202504901A (cg-RX-API-DMAC7.html)
WO (1) WO2020132197A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414827B2 (ja) * 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11840546B2 (en) * 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
KR102961396B1 (ko) 2022-11-28 2026-05-08 계명대학교 산학협력단 신규한 pim 키나아제 억제제 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2018165569A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
DE602005023763D1 (de) 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101150581B1 (ko) * 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド 肝臓の増殖を増大させる方法
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
MX2015005375A (es) 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3500571T3 (pl) 2016-08-17 2021-06-28 Children's Hospital Medical Center Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US11371744B2 (en) 2016-09-15 2022-06-28 Awi Licensing Llc Ceiling system with air movement
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US11840546B2 (en) 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2018165569A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods

Also Published As

Publication number Publication date
JP2022514650A (ja) 2022-02-14
SG11202106582YA (en) 2021-07-29
JP2024045155A (ja) 2024-04-02
TWI852968B (zh) 2024-08-21
CR20210336A (es) 2021-12-06
CN120208959A (zh) 2025-06-27
TW202039502A (zh) 2020-11-01
IL284139A (en) 2021-08-31
PE20220277A1 (es) 2022-02-25
JP7723068B2 (ja) 2025-08-13
AU2019401649B2 (en) 2025-08-28
CN114787160A (zh) 2022-07-22
AU2019401649A1 (en) 2021-07-08
MX2021007426A (es) 2021-09-08
CO2021008117A2 (es) 2021-09-20
EP3898627A1 (en) 2021-10-27
CA3124088A1 (en) 2020-06-25
CL2021001656A1 (es) 2021-12-17
US11459329B2 (en) 2022-10-04
IL284139B1 (en) 2025-02-01
US20240309008A1 (en) 2024-09-19
ECSP21044843A (es) 2021-09-30
JP7414827B2 (ja) 2024-01-16
US20200199131A1 (en) 2020-06-25
MA54551A (fr) 2021-10-27
US20220315595A1 (en) 2022-10-06
PH12021551446A1 (en) 2021-12-06
BR112021011948A2 (pt) 2021-09-08
TW202504901A (zh) 2025-02-01
US12030889B2 (en) 2024-07-09
IL318278A (en) 2025-03-01
WO2020132197A1 (en) 2020-06-25
KR20210116488A (ko) 2021-09-27
IL284139B2 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
US12441731B2 (en) Pyrazolopyrimidine compounds and uses thereof
US12552804B2 (en) Tricyclic heterocycles as FGFR inhibitors
JP7723068B2 (ja) アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US12012409B2 (en) Bicyclic heterocycles as FGFR inhibitors
US20220227752A1 (en) Pyrazolopyridine compounds and uses thereof
EP4175719A1 (en) Tricyclic urea compounds as jak2 v617f inhibitors
TWI895442B (zh) 咪唑并嗒嗪化合物及其用途
HK40057772B (en) Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
HK40057772A (en) Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
EA046773B1 (ru) Соединения имидазопиридазина, активные в качестве ингибиторов alk2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant